Do you want to read an article? Please log in or register.
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Glycemic Control
COMMENTED
Related content
Diabetes - GeneralType 2 DiabetesGlycemic Control
Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials
Diabetes Obes Metab.
Huang CJ, Wang WT, Sung SH, Chen CH, Lip GY, Cheng HM, Chiang CE
doi: 10.1111/dom.13342.
Type 2 DiabetesObesity and Bariatric Surgery
Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials
Diabetes Obes Metab.
Mannucci E, Dicembrini I, Nreu B, Monami M
doi: 10.1111/dom.13888.
COMMENTED
Type 2 Diabetes
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1016/S2213-8587(20)30038-3.
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
Type 2 DiabetesGlycemic Control
Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
Nutr Metab Cardiovasc Dis
Monami M, Candido R, Pintaudi B, Targher G, Mannucci E, of the SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes.
doi: 10.1016/j.numecd.2021.05.010
COMMENTED
Glycemic Control
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care
Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC
doi: 10.2337/dc20-1815
Type 2 DiabetesGlycemic Control
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Lancet Diabetes Endocrinol.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
doi: 10.1016/S2213-8587(17)
Diabetes - GeneralType 2 Diabetes
Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators
Diabetes Care.
Svensson E, Baggesen LM, Johnsen SP, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Thomsen RW
doi: 10.2337/dc16-2271.
COMMENTED
Type 2 DiabetesGlycemic Control
The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-1817.